| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.989 | 0.001 | 0.989 | Interleukin agonist | 0.987 0.001 DBMET02217 0.986 0.001 DBMET00359 | ||
| 0.897 | 0.002 | 0.897 | P-glycoprotein inhibitor | 0.876 0.002 DBMET02217 0.876 0.002 DBMET00359 | ||
| 0.862 | 0 | 0.862 | Immunosuppressant Cyclosporine-like | 0.855 0 DBMET02217 0.703 0 DBMET00359 | ||
| 0.854 | 0 | 0.854 | Calcineurin inhibitor | 0.754 0 DBMET02217 0.784 0 DBMET00359 | ||
| 0.852 | 0.003 | 0.857 | Immunosuppressant | 0.857 0.003 DBMET02217 0.843 0.003 DBMET00359 | DBMET02217 | |
| 0.821 | 0.001 | 0.821 | Interleukin 2 agonist | 0.806 0.001 DBMET02217 0.802 0.001 DBMET00359 | ||
| 0.788 | 0.005 | 0.788 | Immunomodulator | 0.744 0.005 DBMET02217 0.757 0.005 DBMET00359 | ||
| 0.764 | 0.02 | 0.764 | Antiinflammatory | 0.761 0.021 DBMET02217 0.758 0.021 DBMET00359 | ||
| 0.695 | 0.003 | 0.695 | NOS3 expression enhancer | 0.651 0.004 DBMET02217 0.648 0.004 DBMET00359 | ||
| 0.691 | 0.002 | 0.691 | Interleukin 2 antagonist | 0.615 0.003 DBMET02217 0.598 0.003 DBMET00359 | ||
| 0.687 | 0.003 | 0.687 | Interleukin 4 antagonist | 0.628 0.004 DBMET02217 0.601 0.004 DBMET00359 | ||
| 0.655 | 0 | 0.693 | Cyclophilin A inhibitor | 0.693 0 DBMET02217 0.595 0 DBMET00359 | DBMET02217 | |
| 0.642 | 0.014 | 0.642 | Antibacterial | 0.617 0.017 DBMET02217 0.624 0.016 DBMET00359 | ||
| 0.595 | 0.002 | 0.595 | Sodium/bile acid cotransporter inhibitor | 0.576 0.002 DBMET02217 0.572 0.002 DBMET00359 | ||
| 0.555 | 0.015 | 0.555 | Interleukin antagonist | 0.491 0.02 DBMET02217 0.519 0.018 DBMET00359 | ||
| 0.496 | 0.003 | 0.496 | Cell wall synthesis inhibitor | 0.468 0.004 DBMET02217 0.441 0.005 DBMET00359 | ||
| 0.46 | 0.035 | 0.469 | Immunostimulant | 0.469 0.033 DBMET02217 0.444 0.038 DBMET00359 | DBMET02217 | |
| 0.416 | 0.012 | 0.419 | Hepatoprotectant | 0.383 0.015 DBMET02217 0.419 0.012 DBMET00359 | DBMET00359 | |
| 0.375 | 0.008 | 0.375 | Antipruritic | 0.257 0.022 DBMET02217 0.228 0.033 DBMET00359 | ||
| 0.358 | 0.004 | 0.358 | Interleukin 5 antagonist | 0.28 0.004 DBMET02217 0.314 0.004 DBMET00359 | ||
| 0.282 | 0.001 | 0.282 | Dihydroorotate oxidase inhibitor | 0.165 0.002 DBMET02217 0.151 0.003 DBMET00359 | ||
| 0.267 | 0.012 | 0.267 | Antineoplastic antibiotic | 0.242 0.015 DBMET02217 0.242 0.015 DBMET00359 | ||
| 0.259 | 0.007 | 0.259 | Nav1.4 sodium channel blocker | 0.248 0.009 DBMET02217 0.254 0.008 DBMET00359 | ||
| 0.244 | 0.016 | 0.244 | Cell adhesion inhibitor | 0.188 0.028 DBMET02217 0.201 0.024 DBMET00359 | ||
| 0.217 | 0.009 | 0.27 | HIV-1 reverse transcriptase inhibitor | 0.27 0.006 DBMET02217 0.196 0.01 DBMET00359 | DBMET02217 | |
| 0.269 | 0.064 | 0.3 | Platelet antagonist | 0.209 0.095 DBMET02217 0.3 0.052 DBMET00359 | DBMET00359 | |
| 0.21 | 0.008 | 0.21 | Multidrug resistance-associated protein 1 inhibitor | 0.185 0.014 DBMET02217 0.173 0.017 DBMET00359 | ||
| 0.202 | 0.005 | 0.202 | Androgen agonist | 0.202 0.005 DBMET02217 0.161 0.007 DBMET00359 | ||
| 0.258 | 0.061 | 0.258 | DNA synthesis inhibitor | 0.218 0.097 DBMET02217 0.202 0.121 DBMET00359 | ||
| 0.196 | 0.008 | 0.196 | T cell inhibitor | 0.16 0.009 DBMET02217 0.144 0.01 DBMET00359 | ||
| 0.17 | 0.003 | 0.21 | Antiviral (Hepatitis D) | 0.21 0.003 DBMET02217 0.161 0.003 DBMET00359 | DBMET02217 | |
| 0.157 | 0.005 | 0.157 | Somatostatin 1 antagonist | 0.131 0.005 DBMET02217 0.146 0.005 DBMET00359 | ||
| 0.158 | 0.006 | 0.158 | Oxytocin antagonist | 0.124 0.008 DBMET02217 0.147 0.006 DBMET00359 | ||
| 0.192 | 0.044 | 0.192 | ATPase inhibitor | 0.136 0.128 DBMET02217 | ||
| 0.183 | 0.036 | 0.183 | Neurotrophic factor | 0.16 0.05 DBMET02217 0.178 0.039 DBMET00359 | ||
| 0.279 | 0.132 | 0.402 | Antiobesity | 0.402 0.065 DBMET02217 0.251 0.155 DBMET00359 | DBMET02217 | |
| 0.144 | 0.015 | 0.144 | Somatostatin 1 agonist | 0.127 0.02 DBMET02217 0.136 0.017 DBMET00359 | ||
| 0.146 | 0.022 | 0.146 | Cathepsin G inhibitor | 0.079 0.044 DBMET02217 0.118 0.028 DBMET00359 | ||
| 0.156 | 0.034 | 0.156 | Microtubule formation inhibitor | 0.149 0.038 DBMET02217 0.113 0.07 DBMET00359 | ||
| 0.121 | 0.01 | 0.121 | Polo-like kinase-2 inhibitor | 0.107 0.019 DBMET02217 0.12 0.01 DBMET00359 | ||
| 0.11 | 0.006 | 0.11 | Somatostatin 2 antagonist | 0.093 0.007 DBMET02217 0.098 0.007 DBMET00359 | ||
| 0.108 | 0.006 | 0.108 | Somatostatin 5 antagonist | 0.093 0.007 DBMET02217 0.102 0.006 DBMET00359 | ||
| 0.12 | 0.02 | 0.12 | ATPase (Vacuolar H+) inhibitor | 0.109 0.029 DBMET02217 0.1 0.04 DBMET00359 | ||
| 0.114 | 0.015 | 0.114 | GP IIb/IIIa receptor antagonist | 0.076 0.023 DBMET02217 0.102 0.017 DBMET00359 | ||
| 0.236 | 0.141 | 0.265 | Apoptosis antagonist | 0.265 0.113 DBMET00359 | DBMET00359 | |
| 0.098 | 0.005 | 0.098 | Somatostatin 4 antagonist | 0.073 0.006 DBMET02217 0.088 0.005 DBMET00359 | ||
| 0.118 | 0.025 | 0.118 | Factor XII inhibitor | 0.105 0.033 DBMET02217 0.115 0.027 DBMET00359 | ||
| 0.231 | 0.143 | 0.256 | Vasodilator, peripheral | 0.256 0.123 DBMET00359 | DBMET00359 | |
| 0.094 | 0.007 | 0.094 | Nicotinic receptor beta4 subunit antagonist | 0.075 0.009 DBMET02217 0.089 0.007 DBMET00359 | ||
| 0.266 | 0.188 | 0.266 | Calcium channel L-type activator | 0.266 0.188 DBMET00359 | ||
| 0.108 | 0.031 | 0.108 | Chymotrypsin inhibitor | 0.099 0.037 DBMET02217 0.101 0.035 DBMET00359 | ||
| 0.224 | 0.15 | 0.264 | Antithrombotic | 0.264 0.115 DBMET00359 | DBMET00359 | |
| 0.178 | 0.106 | 0.258 | Angiogenesis stimulant | 0.167 0.112 DBMET02217 0.258 0.066 DBMET00359 | DBMET00359 | |
| 0.063 | 0.005 | 0.063 | Somatostatin 3 antagonist | 0.049 0.007 DBMET02217 0.058 0.006 DBMET00359 | ||
| 0.071 | 0.014 | 0.071 | Erythropoietin receptor agonist | 0.053 0.02 DBMET02217 0.067 0.015 DBMET00359 | ||
| 0.075 | 0.02 | 0.075 | Kallikrein 7 inhibitor | 0.072 0.024 DBMET02217 0.072 0.025 DBMET00359 | ||
| 0.058 | 0.004 | 0.058 | Motilin receptor antagonist | 0.048 0.005 DBMET02217 0.046 0.005 DBMET00359 | ||
| 0.075 | 0.021 | 0.075 | Integrin antagonist | 0.044 0.029 DBMET00359 | ||
| 0.064 | 0.013 | 0.064 | Oxytocin agonist | 0.045 0.027 DBMET02217 0.062 0.015 DBMET00359 | ||
| 0.065 | 0.018 | 0.065 | Melanocortin antagonist | 0.057 0.023 DBMET02217 0.059 0.022 DBMET00359 | ||
| 0.062 | 0.015 | 0.062 | Growth hormone release inhibitor | 0.057 0.017 DBMET02217 0.059 0.016 DBMET00359 | ||
| 0.174 | 0.128 | 0.174 | Vasodilator | 0.166 0.135 DBMET00359 | ||
| 0.053 | 0.013 | 0.053 | Vasopressin 2 antagonist | 0.037 0.02 DBMET02217 0.046 0.015 DBMET00359 | ||
| 0.044 | 0.009 | 0.044 | Growth factor receptor-bound protein 2 antagonist | 0.041 0.012 DBMET02217 0.043 0.01 DBMET00359 | ||
| 0.041 | 0.007 | 0.041 | Antidiuretic hormone agonist | 0.035 0.009 DBMET02217 0.039 0.008 DBMET00359 | ||
| 0.051 | 0.018 | 0.051 | Growth hormone secretagogue receptor agonist | 0.046 0.02 DBMET00359 | ||
| 0.04 | 0.01 | 0.04 | Growth hormone releasing factor antagonist | 0.032 0.012 DBMET02217 0.038 0.01 DBMET00359 | ||
| 0.081 | 0.051 | 0.081 | Cell adhesion molecule inhibitor | |||
| 0.039 | 0.013 | 0.039 | Melanocortin 5 antagonist | 0.026 0.018 DBMET02217 0.032 0.015 DBMET00359 | ||
| 0.034 | 0.008 | 0.034 | 1,3-Beta-glucan synthase inhibitor | 0.032 0.011 DBMET02217 0.033 0.009 DBMET00359 | ||
| 0.034 | 0.009 | 0.034 | Vasopressin 1A agonist | 0.032 0.012 DBMET02217 0.033 0.01 DBMET00359 | ||
| 0.045 | 0.023 | 0.045 | Integrin alpha5beta1 antagonist | 0.038 0.032 DBMET02217 0.04 0.03 DBMET00359 | ||
| 0.027 | 0.008 | 0.027 | Vasopressin 1 agonist | 0.025 0.01 DBMET02217 0.026 0.009 DBMET00359 | ||
| 0.063 | 0.046 | 0.067 | Glucagon-like peptide 1 agonist | 0.067 0.043 DBMET00359 | DBMET00359 | |
| 0.026 | 0.01 | 0.026 | Integrin beta3 antagonist | 0.019 0.014 DBMET00359 | ||
| 0.025 | 0.011 | 0.025 | Integrin beta5 antagonist | 0.02 0.015 DBMET02217 0.023 0.012 DBMET00359 | ||
| 0.033 | 0.02 | 0.033 | Histone deacetylase 11 inhibitor | 0.03 0.023 DBMET00359 | ||
| 0.033 | 0.02 | 0.033 | Histone deacetylase class IV inhibitor | 0.03 0.023 DBMET00359 | ||
| 0.042 | 0.03 | 0.042 | Melanocortin 4 antagonist | 0.038 0.034 DBMET00359 | ||
| 0.02 | 0.008 | 0.02 | Vasopressin 2 agonist | 0.017 0.011 DBMET02217 0.019 0.009 DBMET00359 | ||
| 0.031 | 0.023 | 0.031 | Somatostatin agonist | 0.028 0.026 DBMET00359 | ||
| 0.027 | 0.021 | 0.027 | Endothelin receptor antagonist | |||
| 0.038 | 0.033 | 0.038 | Neurokinin 2 antagonist | |||
| 0.019 | 0.017 | 0.019 | Endothelin A receptor antagonist | |||
| 0.034 | 0.032 | 0.034 | Antidiuretic hormone antagonist | |||
| 0.115 | 0.144 | 0.127 | Nitric oxide antagonist | 0.127 0.124 DBMET00359 | DBMET00359 | |
| 0.125 | 0.182 | 0.2 | Catenin beta inhibitor | 0.2 0.032 DBMET02217 | DBMET02217 | |
| 0.091 | 0.229 | 0.163 | Hypolipemic | 0.163 0.124 DBMET02217 | DBMET02217 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |